Sermorelin

Beskrivelse

Sermorelin (sermorelin acetate) is a synthetic 29-amino acid peptide analog of growth hormone-releasing hormone (GHRH 1-29), designed to mimic the body’s natural signal for the pituitary gland to release endogenous human growth hormone (hGH). By binding to GHRH receptors on pituitary somatotroph cells, Sermorelin promotes pulsatile hGH secretion that closely resembles physiological patterns, helping preserve natural feedback loops and potentially reducing risks associated with exogenous hGH therapy. Originally FDA-approved in the 1990s for diagnostic evaluation of growth hormone deficiency and treatment of idiopathic growth hormone deficiency in children, Sermorelin is no longer marketed as an FDA-approved product for those indications as of 2026, though it remains available through compounding pharmacies for off-label use in adults. In wellness, anti-aging, and hormone optimization contexts, Sermorelin is commonly researched or prescribed to support age-related hGH decline, with reported benefits including increased lean muscle mass and strength, accelerated fat metabolism (particularly visceral fat), improved exercise recovery and athletic performance, enhanced sleep quality and deeper REM cycles, better skin elasticity and wound healing, increased bone density, boosted energy levels, improved mood and cognitive function, and overall metabolic health support when combined with proper diet, exercise, and lifestyle modifications. Typical protocols involve subcutaneous injection (often 100-300 mcg once daily at bedtime to align with natural nocturnal GH pulses), with cycles of 3-6 months or longer under medical supervision and regular monitoring of IGF-1, hGH, and other hormone levels. Clinical studies and observational data from its pediatric use, along with adult off-label experiences, suggest meaningful improvements in body composition, vitality, and quality of life for those with suboptimal GH levels. Sermorelin is generally well-tolerated with common side effects including mild injection-site reactions, flushing, headaches, dizziness, or transient fatigue; rarer concerns involve potential water retention, joint discomfort, or insulin sensitivity changes with prolonged use. It requires prescription and oversight due to its status as a controlled peptide in many regions, the need for bloodwork monitoring (IGF-1, glucose, thyroid), and careful patient selection (contraindicated in active malignancy, pituitary tumors, or known hypersensitivity). While more “natural” than direct hGH, Sermorelin is not FDA-approved for adult growth hormone insufficiency, anti-aging, performance enhancement, or metabolic optimization as of 2026—use is off-label/compounded and should only occur under qualified medical guidance with thorough risk-benefit assessment. Always consult a healthcare provider experienced in peptide or hormone therapy for personalized dosing, monitoring, and integration into a comprehensive wellness plan.